Patents by Inventor Alfonso Mendoza Losana

Alfonso Mendoza Losana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230051209
    Abstract: The present invention relates to a composition comprising bacteria of the Delftia genus, specifically a composition comprising Delftia tsuruhatensis as well as the bacteria itself for use in the prevention of malaria transmission and methods of using the compositions for reducing malaria and/or malaria parasite transmission.
    Type: Application
    Filed: July 10, 2020
    Publication date: February 16, 2023
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Alfonso MENDOZA LOSANA, Janneth RODRIGUES
  • Patent number: 11253500
    Abstract: The present invention relates to or a pharmaceutically acceptable salt or ester prodrug thereof for use in the treatment of a mycobacterial infection or disease resulting from a mycobacterial infection, such as tuberculosis.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: February 22, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: David Barros Aguirre, Robert H. Bates, Ruben Gonzalez Del Rio, Alfonso Mendoza Losana, Santiago Ramón García
  • Publication number: 20200289462
    Abstract: The present invention relates to or a pharmaceutically acceptable salt or ester prodrug thereof for use in the treatment of a mycobacterial infection or disease resulting from a mycobacterial infection, such as tuberculosis.
    Type: Application
    Filed: May 4, 2018
    Publication date: September 17, 2020
    Inventors: David BARROS AGUIRRE, Robert H. BATES, Ruben GONZALEZ DEL RIO, Alfonso MENDOZA LOSANA, Santiago RAMÓN GARCÍA
  • Patent number: 8524750
    Abstract: A compound of Formula (I) wherein: either X is N and Y is CR5 or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and Me; R2 is selected from H, OH, OMe and Me; each R3 is independently selected from C1-3alkyl, F, Cl, Br, CF3 and NH2; R4 is selected from Me, CF3, NO2 and CHF2; R5 is selected from H, Me and CHF2; R6 is selected from H and Me; and p is 0-3, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: September 3, 2013
    Assignee: Glaxo Group Limited
    Inventors: Lluis Ballell Pages, Julia Castro Pichel, Raquel Fernandez Menendez, Esther Pilar Fernandez Velando, Silvia Gonzalez Del Valle, Maria Luisa Leon Diaz, Alfonso Mendoza Losana, Matthew James Wolfendale
  • Publication number: 20120095064
    Abstract: A compound of Formula (I) wherein: either X is N and Y is CR5 or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and Me; R2 is selected from H, OH, OMe and Me; each R3 is independently selected from C1-3alkyl, F, Cl, Br, CF3 and NH2; R4 is selected from Me, CF3, NO2 and CHF2; R5 is selected from H, Me and CHF2; R6 is selected from H and Me; and p is 0-3, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.
    Type: Application
    Filed: April 13, 2010
    Publication date: April 19, 2012
    Inventors: Lluis Ballell Pages, Julia Castro Pichel, Raquel Fernandez Menendez, Esther Pilar Fernandez Velando, Silvia Gonzalez Del Valle, Maria Luisa Leon Diaz, Alfonso Mendoza Losana, Matthew James Wolfendale